KCT0009217尚未招募Unknown
A phase II pragmatic study of lazertinib for EGFR-mutant NSCLC with leptomeningeal seeding
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •(1) Patients with pathologically diagnosed non-small cell lung cancer (adenocarcinoma) with confirmed exon 19 deletion or Leu858Arg +/-Thr790Met.
- •(2) Patients with leptomeningeal seeding diagnosed by brain MRI and CSF (CSF cytology positive or atypical cells).
- •(3) Can be enrolled even if they have received prior therapy, including EGFR-TKIs (gefitinib, erlotinib, osimertinib, or lazertinib or other EGFR-TKIs). Prior cytotoxic or immunologic therapy is eligible for enrollment regardless of treatment sequence. However, patients who have used a third-generation EGFR-TKI may be enrolled if they have used a third-generation EGFR-TKI, without LMS, within 3 months prior to enrollment in this study, and subsequently received other systemic therapy (cytotoxic or immuno-oncology) and developed LMS. However, LMS must not have occurred during or within 3 months after use of a third-generation EGFR-TKI.
- •(4) Age 20 years or older
- •(5) ECOG 0-2
- •(6) Minimum life expectancy of 8 weeks
- •(7) Adequate organ function
- •- Absolute neutrophil count (ANC) =1500 cells/mm3
- •- Platelets =100,000 cells/mm3
- •- Total bilirubin =1.5 x upper limit of normal (ULN)
- •- Asparagine aminotransferase (AST) and alanine aminotransferase (ALT) = 5.0 x ULN (
- •- Serum creatinine =1.5 x upper limit of normal (ULN) or CCr = 50 mL/min (calculated using the weight-based Cockcroft- Gault formula).
- •(8) Female patients must be of childbearing potential or agree to use adequate contraception for the duration of the study.
- •Female patients must agree to use adequate contraception and must not be lactating, and for women of childbearing potential, must have a negative pregnancy test prior to initiation of treatment or evidence of non-childbearing status at screening by meeting one of the following criteria: 1.
- •- Postmenopausal women who are >50 years of age and have been amenorrheic for at least 12 months after discontinuation of all exogenous hormonal therapy.
- •- Documented irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingo-oophorectomy; tubal ligation is not permitted.
- •- Women 50 years of age or younger will be considered postmenopausal only if they have been amenorrheic for at least 12 months after discontinuing all exogenous hormonal therapy and their luteinizing hormone (LH) levels and follicle-stimulating hormone (FSH) levels are within the site's postmenopausal range.
- •- Use reliable contraception during sexual intercourse with all partners from the screening period through 12 weeks after discontinuation of study therapy.
- •For male patients who have not had a vasectomy, must agree to all of the following
- •- Use reliable contraception during sexual intercourse with all partners from the screening period until 12 weeks after stopping study therapy.
- •- Not donate sperm from the date of initiation of study therapy until 12 weeks after discontinuation of study therapy.
- •- If male patients wish to have children during the aforementioned period, they should be advised to arrange for freezing of their sperm samples prior to initiation of study therapy.
- •(9) Patients who are willing and able to comply with the protocol.
- •(10) Who have made a voluntary decision to participate in this study and have signed a written informed consent.
- •(11) Patients who can take medication orally or through L-tube, PEG, etc.
排除标准
- •(1) Patients with serious, symptomatic brain metastases, requiring emergency radiation therapy, or using high-dose steroids (high-dose steroid definition: dexamethasone > 10 mg/day) are excluded. Patients with previously diagnosed brain metastases treated with radiotherapy or stereotactic radiosurgery may be enrolled 2 weeks after such treatment if symptoms are stable.
- •(2) Patients who have received 2 or more first or second generation EGFR-TKIs.
- •(3) Uncontrolled systemic disease, including uncontrolled hypertension, active bleeding, or active infection.
- •(4) Patients with documented interstitial lung disease, drug induced interstitial lung disease, or radiation pneumonitis at a level requiring steroid treatment.
- •(5) Unresolved toxicity from prior therapy, > CTCAE grade 1.
- •(6) Pregnant and lactating women.
- •(7) Excluded if they have a prior or coexisting malignancy (but may be enrolled if they have been cured with no recurrence within 5 years).
- •(8) Participants with a history of clinically significant cardiovascular disease, including but not limited to the following
- •- Diagnosis of deep vein thrombosis or pulmonary embolism within 1 month prior to the first dose of study therapy or any of the following within 6 months prior to the first dose of study therapy: myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary artery/peripheral artery bypass grafting, or any wet coronary syndrome. Clinically insignificant thrombosis, such as non-obstructive catheter-related thrombi, is not excluded. 9.
- •- Prolonged QTcF interval >480 msec or clinically significant cardiac arrhythmia or electrophysiologic disease (e.g., implantable cardioverter-defibrillator or uncontrolled atrial fibrillation).
- •- Pericarditis/clinically significant pericardial effusion.
- •- Myocarditis
- •(9) Mental illness or dementia that would interfere with the ability to cooperate with the requirements of this study.
研究者
相似试验
进行中（未招募）
不适用
PHASE II STUDY OF LAPATINIB IN EGFR/HER2NEU POSITIVE ADVANCED CHORDOMA - NDAdvanced chordoma EGFR/Her2Neu positiveMedDRA version: 9.1Level: LLTClassification code 10039492EUCTR2009-014456-29-ITISTITUTO NAZIONALE PER LA CURA TUMORI
已完成
2 期
Phase II study of gefitinib in patients with EGFR mutation positive- advanced non-small cell lung cancernon-small cell lung cancerJPRN-C000000151West Japan Oncology Group25
招募中
2 期
Phase II study of Erlotinib monotherapy in EGFR mutation-negative lung adenocarcinoma excluded biomarkers against EGFR-TKI treatment.lung adenocarcinomaJPRN-UMIN000011411Federation of National Public Service Personnel Mutual Aid Associations TORANOMON HOSPITAL Department of Respiratory Medicine23
招募中
不适用
Phase II study of LAZertinib And pemetrexed in EGFR mUtant NSCLC patients with leptomeningeal carcinomatosisNeoplasmsKCT0005919Seoul National University Hospital43
进行中（未招募）
2 期
Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior LazertinibNon-small Cell Lung CancerNCT05786430Yonsei University87